|
Volume 270,
Number 41,
Issue of October 13, 1995 pp. 24406-24413
©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Molecular
Cloning, Structure, and Expression of Mouse Estrogen-responsive Finger
Protein Efp
CO-LOCALIZATION WITH ESTROGEN RECEPTOR mRNA IN TARGET ORGANS (*)
(Received for publication, May 15, 1995; and in revised form, July
5, 1995)
Akira
Orimo
(1),
Satoshi
Inoue
(1),
Kazuhiro
Ikeda
(1),
Sumihare
Noji
(2),
Masami
Muramatsu
(1)(§)From the
(1)Department of Biochemistry, Saitama
Medical School, 38 Moro-Hongo, Moroyama-machi, Iruma-gun, Saitama
350-04, Japan and the
(2)Department of Biological Science and Technology,
Faculty of Engineering, University of Tokushima, 2-1
Minami-Jyosanjima-machi, Tokushima 770, Japan
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES
ABSTRACT
We have previously identified a human estrogen-responsive gene, efp (estrogen-responsive finger protein), which encodes a
putative transcription regulator (Inoue, S., Orimo, A., Hosoi, T.,
Kondo, S., Toyoshima, H., Kondo, T., Ikegami, A., Ouchi, Y., Orimo, H.,
and Muramatsu, M.(1993) Proc. Natl. Acad. Sci. U. S. A. 90,
11117-11121). Here, we report isolation of mouse Efp cDNA and its
structure containing three cysteine-rich domains (RING finger and B1
and B2 boxes), a coiled-coil domain, and a C-terminal domain. High
levels of Efp mRNA were detected in uterus, ovary, and placenta by
RNase protection assay. By in situ hybridization
histochemistry the transcripts of efp were also detected in
uterus, mammary gland, ovary, and brain, and the co-localization of Efp
and estrogen receptor mRNA was particularly demonstrated in these
female organs. Moreover, the level of Efp mRNA in uterus and brain,
which are known as target organs for estrogen, was up-regulated in
vivo by 17 -estradiol. Furthermore, both the Efp and estrogen
receptor mRNA were stained in the brain vesicles of 11.5-day embryos by
whole mount in situ hybridization. These findings raise the
possibility that efp is an estrogen-responsive gene that
mediates estrogen action in various target organs.
INTRODUCTION
Estrogen plays important roles in the reproductive system as a
sex steroid hormone. It is involved in the growth and development of
female organs such as the uterus and mammary gland. Estrogen receptor
(ER) ( )acts as an estrogen-dependent transcription factor
recognizing and binding to specific estrogen-responsive elements (ERE)
in the enhancer region of target genes and regulating their
transcription directly. Thus, estrogen exerts its action on target
organs by regulating target gene products(1, 2) . ER
has also been identified in the central nervous
system(3, 4) , in the skeletal
system(5, 6) , and in the cardiovascular
system(7, 8) , implying some important roles for
estrogen and estrogen responsive genes in a number of nonreproductive
organs. From the clinical point of view, estrogen replacement therapy
is effective to protect postmenopausal women from osteoporosis (9) and coronary heart disease(10) . Furthermore,
estrogen plays critical roles in carcinogenesis and growth of breast
cancers(11) . In contrast to the wide variety of estrogen
action on different organs, tissues, and cells, estrogen-responsive
genes that are known so far are relatively few and include
vitellogenin(12) , prolactin(13) , pS2(14) ,
uteroglobin(15) , ovalbumin(16) , progesterone
receptor(17) , and lactoferrin(18) . More genes that
mediate estrogen action in a number of organs should be present. To
identify estrogen-responsive genes, we have developed a method
designated ``genomic binding site cloning'' used for
isolation of ERE-containing fragments from human genomic
DNA(19) . Using one of those fragments, we have cloned a novel
estrogen-responsive gene, efp (for estrogen-responsive finger
protein)(20) . The predicted human Efp protein had a RING
finger motif present in a new family of apparent nuclear proteins
including transcription regulators(21, 22) . Human efp contained a consensus ERE sequence at the 3` region that
could act as a downstream estrogen-dependent enhancer, and it was
up-regulated by estrogen in ER-positive cells derived from mammary
gland. Here, we have identified the mouse homologue of human efp. The predicted mouse Efp showed a high degree of
conservation with human Efp. Interesting differential conservation of
different domains of the protein was also noted. Mouse Efp mRNA was
detected in reproductive organs and in the central nervous system by in situ hybridization histochemistry. Northern blot analysis
indicated that the level of Efp mRNA was up-regulated within 2 h in
uterus and brain by 17 -estradiol. Moreover, the co-localized
expression of Efp mRNA with ER mRNA in female reproductive organs and
in brain vesicles of embryos was demonstrated.
EXPERIMENTAL PROCEDURES
Screening of Mouse cDNA Libraries and DNA Sequence
AnalysisA ZAPII (Stratagene) cDNA library prepared from
poly(A) RNA of mouse placenta was screened as
described previously(20) . 600,000 plaques were screened by
hybridization with the P-labeled 2.4-kilobase EcoRI fragment of human Efp cDNA(20) . Sequence
analysis was performed by the dideoxy method according to the
manufacturer's instructions (Sequenase, U.S. Biochemical Corp.).
Southern Blot AnalysisMouse, human, and rat
genomic DNAs were prepared as described(23) . Purified DNA was
digested overnight with restriction enzymes separated in 0.7% agarose
gel. A transferred membrane was hybridized with a P-labeled 522-bp EcoRI fragment encompassing a
part of the cysteine-rich region of mouse Efp cDNA overnight as
described previously(19) .
RNA IsolationTissues of 5-week ICR mice and the
heads of embryos (10.5-, 12.5-, 14.5-, and 18.5-day) were collected and
homogenized. Each total RNA was extracted as described previously (23) for the RNase protection assay. 17 -Estradiol (500
µg/kg) mixed with olive oil was injected subcutaneously into 3-week
female ICR mice. After the injection of 17 -estradiol, uterus and
brain were collected at the indicated hours. RNA was extracted, and
poly(A) RNA was prepared for Northern blot analysis.
RNA ProbesFor in situ hybridization,
antisense and sense RNA probes labeled with digoxigenin-UTP (Boehringer
Mannheim) were produced in vitro from linearized plasmid
bearing a 522-bp EcoRI fragment of mouse Efp cDNA or a
2.1-kilobase EcoRI fragment of mouse ER cDNA(24) . The
mean length of the in vitro transcribed RNA was reduced to
100-200 bp by alkaline hydrolysis(25) . Probes were used
for hybridization at 1 µg/ml. For the RNase protection assay,
antisense RNA probes were generated with [ P]UTP
(Amersham Corp.) in vitro according to the
manufacturer's protocol (Nippongene, Tokyo) from linearized
plasmid bearing a 522-bp EcoRI fragment of mouse Efp cDNA or
an 180-bp XhoI-PstI fragment of mouse ER
cDNA(24) . For internal control, antisense RNA probes were
generated with [ P]UTP in vitro from
linearized plasmid bearing a 114-bp EcoRI fragment of mouse
glyceraldehyde-3-phosphate dehydrogenase cDNA or a 250-bp frgment of
-actin cDNA supplied with the kit.
RNase Protection AssayRNase protection assays
were performed using the Ambion ribonuclease protection assay RPA II
kit (Ambion, Texas). Each 15 µg of total RNA derived from mouse
tissues was hybridized with Efp and -actin RNA probes or ER and
glyceraldehyde-3-phosphate dehydrogenase RNA probes. Each 15 µg of
total RNA derived from the heads of mouse embryos was hybridized with
Efp and -actin RNA probes.
Northern Blot AnalysisFor each sample, 3 µg
of poly(A) RNA from uterus and 10 µg of
poly(A) RNA from brain were separated in 1% agarose.
Northern blot analysis was performed as described
previously(20) . The P-labeled 522-bp EcoRI fragment of mouse Efp cDNA, -actin cDNA fragment
(Nippongene, Tokyo), or glyceraldehyde-3-phosphate dehydrogenase cDNA
fragment was used as the probe. Autoradiography was carried out at
-80 °C with an intensifying screen for 3 days in Efp probe
and for 1 day in -actin cDNA probe. This experiment was performed
three times with consistent results.
Nuclear Extract PreparationNuclear extracts were
prepared as described by Gorski et al.(26) with
several modifications. Mouse placenta was minced finely with scissors,
homogenized in the indicated buffer(26) , loaded on top of the
sucrose cushion containing 2 M sucrose and 10% glycerol, and
centrifuged at 23,000 rpm for 60 min. The nuclear pellet was dissolved
in the indicated buffer, quantitated by measuring absorbance, and
frozen in liquid nitrogen until use.
Antibody Preparation and Western Blot
AnalysisPartial mouse Efp cDNA (amino acids 303-457)
generated by polymerase chain reaction was ligated in the EcoRI-XhoI site of pGEX-4T-1 (Pharmacia Biotech
Inc.), and in-frame fusions were constructed. The fusion protein
expressed in Escherichiacoli was eluted from a
Sepharose 4B column (Pharmacia) by competition with reduced
glutathione(27) . Rabbit polyclonal anti-Efp antiserum was
generated by subcutaneous injection of the fusion protein emulsified in
complete Freund's adjuvant. Western blot analysis was as
described previously(20) . The membrane was probed with the
anti-mouse Efp antibody (1:10,000) and then anti-rabbit lgG (Fc)
conjugated with alkaline phosphatase (1:7500).
In Situ HybridizationTissues of 5-week ICR mice
were collected and fixed. In situ hybridization was performed
essentially as described previously(28) . Slides were
hybridized with mouse Efp or ER RNA probe overnight at 50 °C and
reacted with anti-digoxigenin-alkaline phosphatase (Boehringer
Mannheim) (1:700) diluted in blocking reagent. Then color reactions
were performed with nitro blue tetrazolium and X-phosphate (Boehringer
Mannheim) overnight.
Whole Mount in Situ HybridizationWhole mount in situ hybridization was performed as described by
Wilkinson(29) . 11.5-day embryos were removed from the uteruses
of pregnant ICR mice, fixed in 4% paraformaldehyde in
phosphate-buffered saline at 4 °C for 12 h, and hybridized with the
digoxigenin-labeled mouse Efp and ER RNA probes.
RESULTS
Isolation of Mouse EfpSeven clones were
isolated by the screening the mouse placenta cDNA library (see
``Experimental Procedures''). All the clones were found to be
derived from the same RNA by restriction mapping and partial
sequencing. The clone N3 that had the longest insert was sequenced
full-length for both strands and was found to have the longest open
reading frame (634 amino acids) that showed the same domain
organization and a high degree of sequence homology to the human Efp (Fig. 1A). An isoform cDNA lacking 99 bp was also
identified, which might be derived from an alternative splicing (Fig. 1A).
Figure 1:
Molecular
structure of the mouse Efp. A, nucleotide and deduced amino
acid sequences of mouse Efp cDNA ( N3). The deduced amino acids are
shown below their respective codons. The TAG stop codon (*)
and the polyadenylation signal are underlined. The long
3`-untranslated region contains two (GT) repeats,
which are also underlined. An imperfect palindromic sequence
of ERE is doubleunderlined. Conserved residues,
including cysteines/histidines, in three cysteine-rich domains that may
be involved in zinc finger-like structures are circled. They
contain the RING finger motif (amino acids 13-53), B1 box (amino
acids 106-142), and B2 box (amino acids 156-185). The
potential coiled-coil domain (amino acids 190-313) is underlined. The potential C-terminal domain (amino acids
462-632) is indicated by a grayline. The
deleted 33 amino acids (amino acids 395-427) resulting in the
short form cDNA are indicated by opentriangles. B, diagrammatic representation and comparison of conserved
domains between mouse and human Efp. The cysteine-rich (RING finger, B1
box, and B2 box domains), coiled-coil domain, and C-terminal domain are
shown as distinctive boxes. The homology of amino acids
between mouse and human Efp is shown below the respective
conserved domains. The number of amino acids in the spacing among the
respective domains is shown in parentheses. C,
genomic Southern blot analysis of efp in mouse and other
species. Cross-species genomic Southern blot analysis shows the
presence of homologue or related genes in human and rat. Lanes1, 2, and 3 contained genomic DNA
digested with EcoRI from human, mouse, and rat, respectively.
Sizes were estimated using DNA restricted with HindIII.
Structure of Mouse EfpMouse Efp cDNA ( N3)
encodes a protein of calculated relative molecular mass (M ) of 71,768, containing the RING finger, B1 box,
B2 box, coiled-coil, and C-terminal domains (Fig. 1A).
The RING finger and B1 and B2 box domains form the cysteine-rich region
of the Efp. An alignment between the predicted mouse and human Efp
proteins shows a high degree of homology in the cysteine-rich sequence
domain (89%) including RING finger (83%), B1 box (92%), B2 box (93%),
and C-terminal (88%) domains at the amino acid level (Fig. 1B). The coiled-coil domain (67%) and the spacing
region between coiled-coil and C-terminal domains show a lower degree
of homology.
The efp Gene in the Mouse GenomeA single band of
3.5 kilobases was detected from EcoRI-digested mouse genomic
DNA by cross-species genomic Southern blot analysis (Fig. 1C). The mouse Efp cDNA probe strongly hybridized
with human as well as rat DNA.
The Expression of Mouse Efp and Its Estrogen
ResponsivenessThe RNase protection assay showed that relatively
abundant Efp mRNA was present in uterus, ovary, and placenta, whereas
it was detected at a medium level in mammary gland and at lower levels
in brain and liver (Fig. 2A). In other organs such as
spleen, kidney, heart, lung, and thymus, the level of Efp mRNA was also
relatively low (data not shown). On the other hand, the ER mRNA was
detected at high amounts in uterus and ovary (Fig. 2B).
Western blot analysis showed the existence of Efp in placenta (Fig. 2C). By immunoblotting with an anti-mouse Efp
antibody a specific band was detected in the nuclear extract derived
from mouse placenta (Fig. 2C). The size of the band
agreed well with the predicted M .
Figure 2:
The tissue distributions of efp and ER transcripts. A, RNase protection assay with Efp
and -actin RNA probe. Lane1, M is the HapII-digested pBR 322 as size marker (calibration in bp); lane2, undigested Efp RNA probe; lane3, undigested -actin RNA probe; lanes4-9, placenta, uterus, ovary, mammary gland, brain,
and liver RNA, respectively. 15 µg of total RNA was used in each
assay. Full-length protected fragments for each probe are indicated. As
an internal control, -actin RNA probe was included in the Efp
assay. The Efp mRNA was shown to be expressed in uterus, ovary, and
placenta at relatively high levels followed by mammary gland and liver.
The Efp mRNA in brain was detected as a faint band. B, RNase
protection assay with ER and glyceraldehyde-3-phosphate dehydrogenase
RNA probe. Lane1, M is the HapII-digested pBR 322 as size marker (calibration in bp); lane2, undigested ER RNA probe; lane3, undigested glyceraldehyde-3-phosphate dehydrogenase
RNA probe; lane4, yeast total RNA control; lanes5-10, placenta, uterus, ovary, mammary gland,
brain, and liver RNA, respectively. 15 µg of total RNA was used in
each assay. Full-length protected fragments for each probe are
indicated. As an internal control, glyceraldehyde-3-phosphate
dehydrogenase RNA probe was included in the ER assay. The ER mRNA was
shown to be expressed in uterus and ovary at high levels. C,
Western blot analysis shows the existence of Efp. Nuclear extract
prepared from mouse placenta was separated on a 10% SDS-polyacrylamide
gel and electroblotted to polyvinylidene difluoride membrane (Millipore
Corp.). Western blot analysis with anti-mouse Efp antibody (1:10,000)
detects a 70-kDa native protein with the M predicted from Efp cDNA. Molecular masses are given in
kilodaltons.
In situ hybridization histochemical studies detected transcripts of efp in mouse uterus, mammary gland, ovary, and brain. In
uterus, Efp mRNA was localized predominantly over endometrium (Fig. 3A). The highest stain density was found in
columnar epithelial cells of uterus, and lower levels were found in
stromal cells of the lamina propria (Fig. 3A) and in
smooth muscle cells of the myometrium (data not shown). No staining was
seen with the sense Efp RNA probe (Fig. 3B). The
hybridization signal with antisense ER RNA probe showed the
co-localization of Efp and ER mRNA in endometrium (Fig. 3, A and C). Both Efp and ER mRNA were detected in luminal
epithelial cells in mammary gland (Fig. 3, D and F), while no staining was found with sense Efp RNA probe (Fig. 3E). In mouse ovary, only granulosa cells but not
thecal cells were well stained by antisense Efp RNA probe (Fig. 3G). Antisense ER RNA probe stained the granulosa
cells well and also stained a part of the thecal cells (Fig. 3, G and I). No staining was detected with sense Efp RNA
probe here too (Fig. 3H). In mouse brain, Efp mRNA was
shown widely distributed. The Efp mRNA-containing neurons were found
with greater cell densities on the sections of cerebral cortex (Fig. 4A) and hypothalamus including the ventromedial
hypothalamic nucleus (Fig. 4, B and D), while
no staining was detected with sense Efp RNA probe (Fig. 4C).
Figure 3:
In situ hybridization
histochemistry of Efp mRNA in reproductive organs. Photographs A-C represent a set of serial uterus sections. D-F represent a set of serial mammary gland sections. G-I represent a set of serial ovary sections. (A, D, and G) are hybridized with the Efp
antisense probe. (B, E, and H) are
hybridized with the Efp sense probe for the negative control. (C, F, and I) are hybridized with the ER
antisense probe. To facilitate orientation, the epithelium (e)
and the stroma (s) of uterus and granulosa cells (g)
and thecal cells (t) of ovary are indicated. The scalebar indicates 1 µm (A-C) and 100
µm (D-I). The co-localization of Efp and ER mRNA in
female organs is shown.
Figure 4:
In situ hybridization
histochemistry of Efp mRNA in brain. Photograph A represents a
frontal section of cerebral cortex. B-D represent
frontal sections of hypothalamus. A, B, and D are hybridized with the Efp antisense probe. C is
hybridized with the Efp sense probe for the negative control. An arrow indicates the ventromedial hypothalamic nucleus, and 3V indicates the third ventricle. In a higher magnification (D), Efp mRNA is significantly expressed in neurons. The scalebar indicates 1000 (A-C) and 100 µm (D).
To examine estrogen responsiveness of the
mouse efp gene in vivo, the effect of estrogen
administration on the amount of Efp mRNA was studied in uterus and
brain. By Northern blot analysis, a 6.0-kilobase transcript of mouse efp was detected in these organs, and its amount was increased
by subcutaneous injection of 17 -estradiol (500 µg/kg) to 2.5
times in uterus and 2.0 times in brain as early as 2 h, using
-actin mRNA as an internal standard and then returned to normal
level by 4-6 h (Fig. 5).
Figure 5:
Mouse Efp mRNA was regulated by estrogen
in uterus and brain. Northern blot analysis shows that the level of Efp
mRNA is elevated at 2 h in uterus and brain after subcutaneous
injection of 17 -estradiol (500 µg/kg) into 3-week ICR female
mice. The level of Efp mRNA is decreased 4 and 6 h
thereafter.
The Expression of Efp mRNA in Mouse EmbryosThe
expression of Efp mRNA in the heads of embryos was also studied by
RNase protection assay. The Efp mRNA was detected from 10.5 days to
18.5 days, the level being highest at 16.5 days (Fig. 6). By
whole mount in situ hybridization, Efp as well as ER mRNA
staining was found predominantly in brain vesicles of 11.5-day mouse
embryo (Fig. 7, A and C). The Efp mRNA
staining was distributed over the regions corresponding to
telencephalon, mesencephalon, and metencephalon, but it was much less
over the region corresponding to spinal cord (Fig. 7A).
No staining was detected with sense Efp RNA probe (Fig. 7B). The staining of ER mRNA was also present in
the regions corresponding to telencephalon and mesencephalon, whereas
it was rather low in metencephalon and spinal cord (Fig. 7C). In Fig. 7, D and F,
paraffin-embedded in situ hybridization also showed that both
the Efp and ER mRNA were expressed in telencephalon, while no staining
was detected with sense Efp RNA probe (Fig. 7E).
Figure 6:
Detection of Efp mRNA in mouse embryos
during gestation. The photograph represents biochemical
detection of the efp transcript in the heads of mouse embryos
during the gestation. The RNase protection assay was performed with Efp
and -actin RNA probe. Lane1, M is the HapII-digested pBR 322 as size marker (calibration in bp); lane2, undigested Efp RNA probe; lane3, undigested -actin RNA probe; lane4, yeast total RNA control; lanes5-9, 10.5-, 12.5-, 14.5-, 16.5-, and 18.5-day
embryo RNA, respectively. 15 µg of total RNA was used in each
assay. Full-length protected fragments for each probe are indicated. As
an internal control, the -actin RNA probe was included in the Efp
assay. The transcript of efp was detected from day 10.5 to day
18.5 in the heads of embryos.
Figure 7:
In situ hybridization
histochemistry of Efp mRNA in mouse embryos. Photographs A-C represent the lateral view of 11.5-day whole mount embryos. D-E represent a set of serial sagittal sections of the
head in embryo, and the regions of telencephalon and lateral ventricle
are indicated. A and D are hybridized with the Efp
antisense RNA probe. B and E are hybridized with the
Efp sense RNA probe. C and F are hybridized with the
ER antisense RNA probe. te, telencephalon; ms,
mesencephalon; mt, metencephalon; lv, lateral
ventricle. Scalebar, 1000 µm (D-F).
DISCUSSION
Isolation of Mouse Efp and Comparison with Other
Proteins in the RING Finger FamilyIn this work, the mouse
homologue of the human Efp has been cloned and characterized. Human efp was isolated as an estrogen-responsive gene by genomic
binding site cloning using a recombinant ER protein(20) . The
predicted mouse Efp shows a high degree of conservation with human Efp
over the cysteine-rich sequence and C-terminal domain, with a higher
divergence at their spacing region and coiled-coil domain.
Cross-species genomic Southern blot analysis using mouse Efp cDNA probe
suggests that mouse efp exists as a single copy in mouse
genome. Indeed, this gene was mapped to a single locus in the mouse
chromosome 11C region (30) . Strong cross-hybridizing bands in
human and rat DNA suggest that efp is highly conserved in
mammalian species. The cysteine-rich regions at the amino terminus of
Efp fit the consensus of this new family of zinc finger motifs called
the RING finger, B1 box, and B2 box(21, 22) .The
seven RING finger containing proteins (i.e. the human PML or
Myl protein(31, 32, 33, 34) , the
mouse T18 protein(35) , the mouse Rpt-1 regulatory
protein(36) , the human Rfp protein and the related Ret fusion
protein(37) , the human 52-kDa SS-A/Ro
autoantigen(38, 39) , XNF7 from Xenopus(40) , and PWA33 from the newt Pleurodeles
waltl(41) are known to have B box domains so far. All of
these B box-containing proteins have a coiled-coil domain present
immediately carboxyl-terminal to the B boxes(34, 40) .
Amino acid comparison of proteins with putative coiled-coil domain
shows that there is little sequence identity except for mouse and human
Efp. However, there is conservation of heptad repeats of hydrophobic
amino acids over this region. PML could form a complex with
PML-RAR (presumably as a heterodimer) by the coiled-coil domain
comprised of heptad repeats(34) . The coiled-coil structure
could be required for dimer formation. Amino acid comparison of
proteins with the putative C-terminal domain shows the existence of
conserved residues(38, 42) . Excepting the PML, T18,
and Rpt-1, the RING-B box-containing subfamily has a C-terminal domain,
which is highly conserved, though nothing is known about its function. A number of proteins having the RING finger motif are involved in
regulating gene expression. For example, Rpt-1 is a down-regulator of
the interleukin-2 receptor and human immunodeficiency virus type 1
genes(36) . The Rfp is proposed to be a transcription regulator
in spermatogenesis(37) . XNF-7 is a putative transcription
regulator expressed maternally in Xenopus laevis(40) .
PWA33 is associated with the nascent transcripts on the lampbrush
chromosome loops and likely to be a regulatory protein during early
development (41) . These data suggest that Efp may also be a
transcription regulator, although rigorous proof awaits more
experimentation. Several RING finger-containing proteins are
implicated in cell transformation. For example, PML produces a fusion
protein with the retinoic acid receptor in acute
promyelocytic
leukemia(31, 32, 33, 34) . T18 is a
transforming mouse fusion protein with the B-raf proto-oncogene(35) . Human Rfp fused with the ret proto-oncogene acquires transforming activity(37) . Mouse bmi-1 cooperates with the myc oncogene in lymphoma
development(43, 44) . Freemont et
al.(45, 46) report that two oncogenes, c-cbl(47) associated with lymphoma and mdm-2(48) , which forms a complex with p53 protein and
inhibits its transactivation, also contain a RING finger motif.
Recently, the BRCA1 gene that was identified as a
tumor-suppressor gene for the early-onset breast cancer and ovarian
tumor by linkage analysis has been cloned(49) . Interestingly,
the BRCA1 gene also had the RING finger motif and
was localized in the chromosome 17q 21.3 locus close to 17q 23.1, where
human Efp was localized(30) . Efp is a member of the RING-B
box-containing subfamily that includes PML and T18, which raises an
interesting possibility that the Efp may be involved in cell
transformation or make a fusion protein related to oncogenesis.
The Expression of the efp GeneThe Efp mRNA was
found to be expressed at a relatively high level in reproductive organs
in which ER mRNA was highly expressed. In other organs, the expression
of Efp mRNA was relatively low. The high staining of Efp and ER mRNA in
mouse uterus examined by in situ hybridization histochemistry
was co-localized in epithelial cells of the endometrium. This is in
agreement with the previous
immunohistochemistry(50, 51, 52) and in
situ hybridization histochemistry (53) data that showed a
high staining of ER mRNA in epithelial cells of the uterus. In human
mammary gland, it was reported that ER mRNA was expressed in luminal
epithelial cells(54, 55) . Here, we showed that Efp as
well as ER mRNA was also expressed in luminal epithelial cells. In the
ovary, however, Efp mRNA was rather restricted to the granulosa cells.
By contrast, ER mRNA was found predominantly in granulosa cells but
also in thecal cells at a low level. This distribution for ER mRNA is
consistent with the previous immunohistochemical data showing that
granulosa cells are the major site of ER in
ovary(52, 56) .The co-localization of Efp and ER
mRNA in a number of tissues supports the idea that efp is an
estrogen-responsive gene in vivo in these organs. Previous in situ hybridization histochemistry of ER (3) and I-labeled estrogen autoradiography (4) showed
that ER mRNA was widely distributed among neurons of rat brain, with
the greatest density in medial preoptic and ventromedial nuclei of
hypothalamus. The presence of Efp mRNA-containing neurons in the
ventromedial hypothalamic nucleus may suggest that Efp is involved in
the regulation of reproductive behavior or other behaviors through
estrogen. Northern blot analysis showed that the expression of mouse
Efp mRNA was up-regulated by estrogen within 2 h in uterus as well as
in brain in vivo. Human efp was also
transcriptionally regulated by estrogen at a short response time
(within 2 h) in ER-positive cells derived from mammary
gland(20) . Mouse efp and human efp contain
ERE sequences in the 3`-untranslated region. An ERE in mouse efp is an imperfect palindromic sequence (AGGGCAGGGTGACCT) (Fig. 1A), but it is known that an imperfect
palindromic ERE sequence can actually function (e.g. in the
cases of pS2 (14) and prolactin(13) ). This imperfect
palindromic ERE of mouse efp might act as a downstream
estrogen-dependent enhancer just like the ERE of human efp.
Further analysis is required to establish the role of this sequence. In embryo, Efp mRNA was detected in the head during the gestation by
RNase protection assay and also detected throughout the developing
brain vesicles by in situ hybridization histochemistry. ER
mRNA was also detected in the heads of 10.5- and 12.5-day embryos by
the reverse transcriptase-polymerase chain reaction method and in the
heads of 14.5-18.5-day embryos by RNase protection assay (data
not shown), although the level of ER mRNA in 10.5- and 12.5-day embryos
was shown to be rather low. The expression of Efp and ER mRNA during
embryogenesis may be related to the regulation of brain development in
terms of sexual dimorphism, etc. In a mouse ER gene targeting
model(57, 58) , the female homozygote was found to be
infertile, having a hypoplastic uterus, hyperemic cystic ovary, and
decreased skeletal mineralization, and showed abnormal sexual behavior.
A germ line mutation of the ER gene in humans, resulting in estrogen
insensitivity syndrome, was also identified recently(59) . The
affected male patient was tall, because of the failure of epiphyseal
closure, and had low bone mineral density despite otherwise normal
pubertal development. These studies suggest that ER is indispensable at
least for female fertility, maturation of the female genital tract,
bone maturation, and normal epiphyseal closure, although the disruption
of the ER gene is not necessarily lethal. In the hierarchy of
estrogen action that we have postulated(20) , it is assumed
that Efp is a candidate for the estrogen-responsive transcription
factor. The short response time (2 h) of efp to estrogen in vivo is in line with this prediction. It is possible
that Efp is involved in physiologic actions of estrogen (e.g. maturation of reproductive organs during secondary sexual
development, menstrual cycle, pregnancy, bone maturation, reproductive
behavior, and/or carcinogenesis). The mouse targeting model of efp that is now under way would help clarify these points. The data
presented here could be utilized in future studies of gene targeting as
well as transgenic expression. Furthermore, we believe that the
isolation of more estrogen-responsive genes and the analyses of their
functions would be essential to understand the mechanism of diverse
estrogen actions in various organs.
FOOTNOTES
- *
- The
costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore by hereby marked
``advertisement'' in accordance with 18 U.S.C.
Section 1734 solely to indicate this fact.
The nucleotide
sequence(s) reported in this paper has been submitted to the
GenBank(TM)/EMBL Data Bank with accession number(s)
D63902[GenBank]. - §
- To
whom reprint requests should be addressed: Dept. of Biochemistry,
Saitama Medical School, 38 Moro-Hongo, Moroyama-machi, Iruma-gun,
Saitama 350-04, Japan. Tel: 81-492-76-1490; Fax: 81-492-94-9751.
- (
) - The abbreviations used are: ER, estrogen
receptor; ERE, estrogen-responsive element(s); bp, base pair(s); PML,
promyelocytic leukemia.
ACKNOWLEDGEMENTS
We thank Dr. M. Parker for the gift of murine ER cDNA
probe, Dr. H. Toyoshima for the gift of mouse placenta cDNA library,
and M. Hihara for expert technical assistance. We thank also Drs. H.
Ohuchi, H. Yoshioka, R. Sakai, Y. Watanabe, T. Noda, and T. Hosoi for
helpful comments and discussion.
REFERENCES
- Evans, R. M. (1988) Science 240,889-895
[Abstract/Free Full Text]
- Green, S., and Chambon, P. (1988) Trends Genet. 4,309-314
[CrossRef][Medline]
[Order article via Infotrieve]
- Simerly, R. B., Chang, C., Muramatsu, M., and Swanson, L. W. (1990) J. Comp. Neurol. 294,76-95
[CrossRef][Medline]
[Order article via Infotrieve]
- Toran-Allerand, C. D., Miranda, R. C., Hochberg, R. B., and MacLusky, N. J. (1992) Brain Res. 576,25-41
[CrossRef][Medline]
[Order article via Infotrieve]
- Komm, B. S., Terpening, C. M., Benz, D. J., Graeme, K. A., Gallegos, A., Korc, M., Greene, G. L., O'Malley, B. W., and Haussler, M. R. (1988) Science 241,81-84
[Abstract/Free Full Text]
- Eriksen, E. F., Colvard, D. S., Berg, N. J., Graham, M. L., Mann, K. G., Spelsberg, T. C., and Riggs, B. L. (1988) Science 241,84-86
[Abstract/Free Full Text]
- Stumpf, W. E., Sar, M., and Aumüller, G. (1977) Science 196,319-321
[Abstract/Free Full Text]
- Orimo, A., Inoue, S., Ikegami, A., Hosoi, T., Akishita, M., Ouchi, Y., Muramatsu, M., and Orimo, H. (1993) Biochem. Biophys. Res. Commun. 195,730-736
[CrossRef][Medline]
[Order article via Infotrieve]
- Christiansen, C., Riis, B. J., Nilas, L., Rodbro, P., and Deftos, L. (1985) Lancet 2,800-801
[CrossRef][Medline]
[Order article via Infotrieve]
- Stampfer, M. J., Willett, W. C., Colditz, G. A., Rosner, B., Speizer, F. E., and Hennekens, C. H. (1985) N. Engl. J. Med. 313,1044-1049
[Abstract]
- Henderson, B. E., Ross, R. K., and Pike, M. C. (1991) Science 254,1131-1138
[Abstract/Free Full Text]
- Walker, P., Germond, J., Brown-Luedi, M., Givel, F., and Wahli, W. (1984) Nucleic Acids Res. 12,8611-8826
[Abstract/Free Full Text]
- Maurer, R. A., and Notides, A. C. (1987) Mol. Cell. Biol. 7,4247-4254
[Abstract/Free Full Text]
- Berry, M., Nunez, A.-M., and Chambon, P. (1989) Proc. Natl. Acad. Sci. U. S. A. 86,1218-1222
[Abstract/Free Full Text]
- Müller, H., and Beato, M. (1980) Eur. J. Biochem. 112,235-241
[Medline]
[Order article via Infotrieve]
- Tora, L., Gaub, M. P., Marder, S., Dierich, A., Bellard, M., and Chambon, P. (1988) EMBO J. 7,3771-3778
[Medline]
[Order article via Infotrieve]
- Kastner, P., Krust, A., Turcotte, B., Stropp, U., Tora, L., Gronemeyer, H., and Chambon, P. (1990) EMBO J. 9,1603-1614
[Medline]
[Order article via Infotrieve]
- Nelson, K. G., Sakai, Y., Eitzman, B., Steed, T., and McLachlan, J. (1994) Cell Growth & Differ. 5,919-935
- Inoue, S., Kondo, S., Hashimoto, M., Kondo, T., and Muramatsu, M. (1991) Nucleic Acids Res. 19,4091-4096
[Abstract/Free Full Text]
- Inoue, S., Orimo, A., Hosoi, T., Kondo, S., Toyoshima, H., Kondo, T., Ikegami, A., Ouchi, Y., Orimo, H., and Muramatsu, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,11117-11121
[Abstract/Free Full Text]
- Freemont, P. S., Hanson, I. M., and Trowsdale, J. (1991) Cell 64,483-484
[CrossRef][Medline]
[Order article via Infotrieve]
- Reddy, B. A., Etkin, L. D., and Freemont, P. S. (1992) Trends Biol. Sci. 17,344-345
- Sambrook, J., Fritsch, F., and Maniatis, T. (1989) Molecular Cloning; A Laboratory Manual , 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
- White, R., Lees, J. A., Needham, M., Ham, J., and Parker, M. (1987) Mol. Endocrinol. 1,735-744
[Abstract/Free Full Text]
- Cox, K. H., DeLeon, D. V., Angerer, L. M., and Angerer, R. C. (1984) Dev. Biol. 101,485-502
[CrossRef][Medline]
[Order article via Infotrieve]
- Gorski, K., Carneiro, M., and Schibler, U. (1986) Cell 47,767-776
[CrossRef][Medline]
[Order article via Infotrieve]
- Sakai, R., Iwamatsu, A., Hirano, N., Ogawa, S., Tanaka, T., Mano, H., Yazaki, Y., and Hirai, H. (1994) EMBO J. 13,3748-3756
[Medline]
[Order article via Infotrieve]
- Noji, S., Takahashi, N., Nohno, T., Koyama, E., Yamaai, T., Muramatsu, M., and Taniguchi, S. (1990) Acta Histochem. Cytochem. 23,353-357
- Wilkinson, D. G. (ed) (1992) In Situ Hybridization: A Practical Approach , IRL Press, Oxford
- Inoue, S., Orimo, A., Matsuda, Y., Inazawa, J., Emi, M., Nakamura, Y., Hori, T., and Muramatsu, M. (1995) Genomics 25,581-583
[CrossRef][Medline]
[Order article via Infotrieve]
- Kakizuka, A., Miller, W. H., Umesono, K., Warrell, R. P., Frankel, S. R., Murty, V. V. V. S., Dmitrovsky, E., and Evans, R. M. (1991) Cell 66,663-674
[CrossRef][Medline]
[Order article via Infotrieve]
- de The, H., Lavau, C., Marchio, A., Chomienne, C., Degos, L., and Dejean, A. (1991) Cell 66,675-684
[CrossRef][Medline]
[Order article via Infotrieve]
- Goddard, A. D., Borrow, J., Freemont, P. S., and Solomon, E. (1991) Science 254,1371-1374
[Abstract/Free Full Text]
- Kastner, P., Perez, A., Lutz, Y., Rochette-Egly, C., Gaub, M.-P., Durand, B., Lanotte, M., Berger, R., and Chambon, P. (1992) EMBO J. 11,629-642
[Medline]
[Order article via Infotrieve]
- Miki, T., Fleming, T. P., Crescenzi, M., Molloy, C. J., Blam, S. B., Reynolds, S. H., and Aaronson, S. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,5167-5171
[Abstract/Free Full Text]
- Patarca, R., Schwartz, J., Singh, R. P., Kong, Q. T., Murphy, E., Anderson, Y., Sheng, F. Y. W., Singh, P., Johnson, K. A., Guarnagia, S. M., Durfee, T., Blattner, F., and Cantor, H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85,2733-2737
[Abstract/Free Full Text]
- Takahashi, M., Inaguma, Y., Hiai, H., and Hirose, F. (1988) Mol. Cell. Biol. 8,1853-1856
[Abstract/Free Full Text]
- Chan, E. K. L., Hamel, J. C., Buyon, J. P., and Tan, E. M. (1991) J. Clin. Invest. 87,68-76
- Itoh, K., Itoh, Y., and Frank, M. B. (1991) J. Clin. Invest. 87,177-186
- Reddy, B. A., Kloc, M., and Etkin, L. D. (1991) Dev. Biol. 148,107-116
[CrossRef][Medline]
[Order article via Infotrieve]
- Bellini, M., Lacroix, J.-C., and Gall, J. G. (1993) EMBO J. 12,107-114
[Medline]
[Order article via Infotrieve]
- Jack, L. J. E., and Mather, I. H. (1990) J. Biol. Chem. 265,14481-14486
[Abstract/Free Full Text]
- Haupt, Y., Alexander, W. S., Barri, G., Klinken, S. P., and Adams, J. M. (1991) Cell 65,753-763
[CrossRef][Medline]
[Order article via Infotrieve]
- van Lohuizen, M., Verbeek, S., Scheijen, B., Wientjens, E., van der Gulden, H., and Berns, A. (1991) Cell 65,737-752
[CrossRef][Medline]
[Order article via Infotrieve]
- Lovering, R., Hanson, I. M., Borden, K. L. B., Martin, S., O'Reilly, N. J., Evan, G. L., Rahman, D., Pappin, D. J. C., Trowsdale, J., and Freemont, P. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,2112-2116
[Abstract/Free Full Text]
- Boddy, M. N., Freemont, P. S., and Borden, K. L. B. (1993) Trends Biochem. Sci. 19,198-199
- Blake, T. J., Shapiro, M., Morse, H. C., II, and Langdon, W. Y. (1991) Oncogene 6,653-657
[Medline]
[Order article via Infotrieve]
- Momand, J., Zambetti, G. P., Olson, D. C., George, D., and Levine, A. J. (1992) Cell 69,1237-1245
[CrossRef][Medline]
[Order article via Infotrieve]
- Miki, Y., Swensen, J., Shattuck-Eidens, D., Futreal, P. A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L. M., Ding, W., Bell, R., Rosenthal, J., Hussey, C., Tran, T., McClure, M., Frye, C., Hattier, T., Phelps, R., Haugen-Strano, A., Katcher, H., Yakumo, K., Gholami, Z., Shaffer, D., Stone, S., Bayer, S., Wray, C., Bogden, R., Dayananth, P., Ward, J., Tonin, P., Narod, S., Bristow, P. K., Norris, F. H., Helvering, L., Morrison, P., Rosteck, P., Lai, M., Barrett, J. C., Lewis, C., Neuhausen, S., Cannon-Albright, L., Goldgar, D., Wiseman, R., Kamb, A., and Skolnick, M. H. (1994) Science 7, 66-71
- Yamashita, S., Newbold, R. R., McLachlan, J. A., and Korach, K. S. (1989) Endocrinology 125,2888-2896
[Abstract/Free Full Text]
- Zaino, R. J., Clarke, C. L., Feil, P. D., and Satyaswaroop, P. G. (1989) Endocrinology 125,2728-2734
[Abstract/Free Full Text]
- Iwai, T., Fujii, S., Nanbu, Y., Nonogaki, H., Konishi, I., Mori, T., and Okamura, H. (1991) Endocrinology 129,1840-1848
[Abstract/Free Full Text]
- Koji, T., and Brenner, R. M. (1993) Endocrinology 132,382-392
[Abstract/Free Full Text]
- Petersen, O. W., Hoyer, P. E., and Deurs, B. V. (1987) Cancer Res. 47,5748-5751
[Abstract/Free Full Text]
- Agthoven, T. V., Timmermans, M., Foekens, J. A., Dorssers, L. C. J., and Henzen-Logmans, S. C. (1994) Am. J. Pathol. 144,1238-1246
[Abstract]
- Billiar, R. B., Loukides, J. A., and Miller, M. M. (1992) J. Clin. Endocrinol. Metab. 75,1159-1165
[Abstract]
- Lubahn, D. B., Moyer, J. S., Golding, T. S., Couse, J. F., Korach, K. S., and Smithies, O. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,11162-11166
[Abstract/Free Full Text]
- Korach, K. S. (1994) Science 266,1524-1527
[Abstract/Free Full Text]
- Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., and Korach, K. S. (1994) N. Engl. J. Med. 20,1056-1061
©1995 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
T. Suzuki, T. Urano, T. Tsukui, K. Horie-Inoue, T. Moriya, T. Ishida, M. Muramatsu, Y. Ouchi, H. Sasano, and S. Inoue
Estrogen-Responsive Finger Protein as a New Potential Biomarker for Breast Cancer
Clin. Cancer Res.,
September 1, 2005;
11(17):
6148 - 6154.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. C. Fertuck, J. E. Eckel, C. Gennings, and T. R. Zacharewski
Identification of temporal patterns of gene expression in the uteri of immature, ovariectomized mice following exposure to ethynylestradiol
Physiol Genomics,
October 17, 2003;
15(2):
127 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Tan, B. C. Paria, S. K. Dey, and S. K. Das
Differential Uterine Expression of Estrogen and Progesterone Receptors Correlates with Uterine Preparation for Implantation and Decidualization in the Mouse
Endocrinology,
November 1, 1999;
140(11):
5310 - 5321.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Orimo, S. Inoue, O. Minowa, N. Tominaga, Y. Tomioka, M. Sato, J. Kuno, H. Hiroi, Y. Shimizu, M. Suzuki, et al.
Underdeveloped uterus and reduced estrogen responsiveness in mice with disruption of the estrogen-responsive finger protein gene, which is a direct target of estrogen receptor alpha
PNAS,
October 12, 1999;
96(21):
12027 - 12032.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C Morris-Desbois, V Bochard, C Reynaud, and P Jalinot
Interaction between the Ret finger protein and the Int-6 gene product and co-localisation into nuclear bodies
J. Cell Sci.,
January 10, 1999;
112(19):
3331 - 3342.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-L. C. Liu, E. Golder-Novoselsky, M. H. Seto, L. Webster, J. McClary, and D. A. Zajchowski
The Novel Estrogen-Responsive B Box Protein (EBBP) Gene Is Tamoxifen Regulated in Cells Expressing an Estrogen Receptor DNA-Binding Domain Mutant
Mol. Endocrinol.,
November 1, 1998;
12(11):
1733 - 1748.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
A. Gassama-Diagne, F. Hullin-Matsuda, R. Y. Li, M. Nauze, A. Ragab, V. Pons, C. Delagebeaudeuf, M.-F. Simon, J. Fauvel, and H. Chap
Enterophilins, a New Family of Leucine Zipper Proteins Bearing a B30.2 Domain and Associated with Enterocyte Differentiation
J. Biol. Chem.,
May 18, 2001;
276(21):
18352 - 18360.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1995 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|